歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01672 歌礼制药-B

已收盘 12-15 16:08:35

12.950

-1.570

-10.81%

最高14.330	最低12.870	成交量528.73万
今开13.660	昨收14.520	日振幅10.06%
总市值128.46亿	流通市值128.46亿	总股本9.92亿
成交额7,005万	换手率0.53%	流通股本9.92亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01672","market":"HK","secType":"STK","nameCN":"歌礼制药-B","latestPrice":12.95,"timestamp":1765786115004,"preClose":14.52,"halted":0,"volume":5287300,"delay":0,"floatShares":992000000,"shares":992000000,"eps":-0.3321117388543458,"marketStatus":"已收盘","change":-1.57,"latestTime":"12-15 16:08:35","open":13.66,"high":14.33,"low":12.87,"amount":70045645,"amplitude":0.100551,"askPrice":12.96,"askSize":21000,"bidPrice":12.95,"bidSize":8000,"shortable":3,"etf":0,"ttmEps":-0.2932442596281799,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765848600000},"marketStatusCode":5,"adr":0,"listingDate":1533052800000,"exchange":"SEHK","adjPreClose":14.52,"openAndCloseTimeList":[[1765762200000,1765771200000],[1765774800000,1765785600000]],"volumeRatio":0.398162,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01672","defaultTab":"news","newsList":[{"id":"1122759110","title":"歌礼制药-B公布美国I期研究Asc50的积极顶线结果，这是一种潜在的最佳口服小分子IL-17抑制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1122759110","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122759110?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:00","pubTimestamp":1765789225,"startTime":"0","endTime":"0","summary":"歌礼制药-B公布了美国I期研究Asc50的积极顶线结果，这是一种潜在的最佳口服小分子IL-17抑制剂","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1161","01672","BK1574"],"gpt_icon":0},{"id":"2591116096","title":"歌礼制药-B(01672)：有望成为同类最佳口服小分子IL-17抑制剂ASC50美国I期研究取得积极的顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2591116096","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591116096?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:49","pubTimestamp":1765788597,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，ASC50在美国开展的一项随机、双盲、安慰剂对照的I期临床试验取得积极顶线结果，该试验是在健康受试者中进行的单剂量递增研究，旨在评估ASC50的安全性、耐受性、药代动力学及外周循环的白细胞介素-17A靶向结合特征。ASC50为歌礼自主研发的口服小分子IL-17靶向抑制剂，IL-17在银屑病等多种自身免疫及炎症性疾病中已获充分的生物学验证并具备成熟商业价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","BK1191","BK1515","BK1574","01477","BK1161"],"gpt_icon":0},{"id":"1145036786","title":"港股异动 | 生物技术概念股走低，歌礼制药-B跌超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145036786","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145036786?lang=zh_cn&edition=full","pubTime":"2025-12-15 11:30","pubTimestamp":1765769431,"startTime":"0","endTime":"0","summary":"12月15日，港生物技术概念股走低，$歌礼制药-B(01672)$跌超8%，$圣诺医药-B(02257)$、$复宏汉霖(02696)$、$百济神州(06160)$跌超6%.","market":"us","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1191","01672","BK1574","BK1161"],"gpt_icon":0},{"id":"2591956296","title":"港股开盘 | 恒指低开1% 医药板块跌幅居前 歌礼制药(01672)跌超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591956296","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591956296?lang=zh_cn&edition=full","pubTime":"2025-12-15 09:30","pubTimestamp":1765762255,"startTime":"0","endTime":"0","summary":"恒生指数低开1%，恒生科技指数跌1.34%。盘面上，辅助生殖概念活跃，三胎概念股锦欣生殖开涨约3%；医药板块跌幅居前，歌礼制药跌超5%。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20251215/20251215093112_33389.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251215/20251215093112_33389.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381342.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","BK1161","HHImain","HSI","MHImain","159938","513600","01477","BK4614","02833","BK1515","MCHmain","09939","YANG","01672","BK1191","HSImain"],"gpt_icon":0},{"id":"2590570816","title":"歌礼制药-B(01672)12月12日耗资约437.38万港元回购30万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590570816","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590570816?lang=zh_cn&edition=full","pubTime":"2025-12-12 18:21","pubTimestamp":1765534862,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)公布，2025年12月12日耗资约437.38万港元回购30万股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380983.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1515","BK1191","BK1161","01672","BK1574"],"gpt_icon":0},{"id":"2590545341","title":"歌礼制药-B12月11日主力净流出132.0万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2590545341","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590545341?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:16","pubTimestamp":1765440965,"startTime":"0","endTime":"0","summary":"12月11日, 歌礼制药-B股价跌5.48%，报收15.00元，成交金额7920.3万元，换手率0.52%，振幅7.31%，量比0.40。歌礼制药-B今日主力资金净流出132.0万元，上一交易日主力净流入396.5万元。该股近5个交易日上涨16.20%，主力资金累计净流出3377.5万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入387.6万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211162316a6990e12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211162316a6990e12&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","01477","BK1191","01672","BK1515"],"gpt_icon":0},{"id":"2590456613","title":"GLP-1市场争夺战：礼来替尔泊肽进医保，国产药如何冲出重围？","url":"https://stock-news.laohu8.com/highlight/detail?id=2590456613","media":"药经说","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590456613?lang=zh_cn&edition=full","pubTime":"2025-12-10 17:30","pubTimestamp":1765359058,"startTime":"0","endTime":"0","summary":"事实上，作为全球大热的GLP-1药物，替尔泊肽此次进入医保，意味着成为继司美格鲁肽之后，第二个进入中国医保市场的进口GLP-1产品。竞争格局的急剧恶化是主因，礼来替尔泊肽在全球市场引发的市场热度，无疑盖过了司美格鲁肽，并且让GLP-1市场的天平发生了倾斜。2025年“双十一”期间，京东健康平台上的GLP-1药物成交额增长超过6倍，其中礼来的替尔泊肽排名第一。如今，替尔泊肽正式进入医保目录，无疑将对市场竞争者带来全新的压力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210181144a72f8838&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210181144a72f8838&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01672","BK1574","BK1515"],"gpt_icon":0},{"id":"2590300641","title":"歌礼制药-B(01672)：同类首创FASN抑制剂地尼法司他(ASC40)治疗痤疮的新药上市申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2590300641","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590300641?lang=zh_cn&edition=full","pubTime":"2025-12-10 17:06","pubTimestamp":1765357565,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，董事会宣布同类首创、每日一次口服小分子脂肪酸合成酶抑制剂地尼法司他治疗中重度寻常性痤疮的新药上市申请获中国国家药监局受理。地尼法司他显示出了良好的安全性与耐受性特征。未有观察到与地尼法司他 相关的永久性终止治疗或煺出试验的情况。公司已于近期完成与中国国家药监局就地尼法司他治疗中重度寻常性痤疮的新药上市申请前沟通并收到国家药监局的积极反馈。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01477","BK1574","01672","BK1515","BK1191"],"gpt_icon":0},{"id":"2590184566","title":"每日卖空追踪 | 歌礼制药-B 12月10日卖空量成交12.5万股，卖空比例为1.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590184566","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590184566?lang=zh_cn&edition=full","pubTime":"2025-12-10 16:30","pubTimestamp":1765355423,"startTime":"0","endTime":"0","summary":"歌礼制药-B北京时间12月10日，跌6.15%，卖空量成交12.5万股，较上一交易日减少73.52%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210163456a43f9ebd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210163456a43f9ebd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","01477","01672","BK1574","BK1161","BK1515"],"gpt_icon":0},{"id":"1102748254","title":"港股创新药概念股盘初普跌！歌礼制药-B跌近6%、金斯瑞生物科技跌近5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102748254","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102748254?lang=zh_cn&edition=full","pubTime":"2025-12-10 09:44","pubTimestamp":1765331074,"startTime":"0","endTime":"0","summary":"12月10日，港股创新药概念股盘初普跌，$歌礼制药-B(01672)$跌近6%，$金斯瑞生物科技(01548)$跌近5%，$再鼎医药(09688)$跌超3%，$康方生物(09926)$、$药明康德(00013)$、$药明生物(02269)$跌超2%.","market":"hk","thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"41fbc90a42b871f5da0d5addc6c1afd7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","LU0516422440.USD","LU0326950275.SGD","LU1794554557.SGD","BK1589","LU0516422952.EUR","LU1688375341.USD","ZLAB","01548","01672","BK1610","LU0588546209.SGD","LU2476274720.SGD","LU1880383366.USD","06978","IE00B543WZ88.USD","LU0348766576.USD","LU0516422366.SGD","LU0052750758.USD","09926","LU0572944931.SGD","LU0320764599.SGD","LU0348735423.USD","HK0000306685.HKD","SG9999002562.SGD","BK1574","BK4585","BK1583","BK4139","BK1141","LU0456846285.SGD","LU0348767384.USD","LU0634319403.HKD","LU0516423174.USD","LU0561508036.HKD","LU0181495838.USD","BK1161","LU2488822045.USD","BK1515","HK0000306701.USD","SG9999002463.SGD","IE00B0JY6N72.USD","LU0359201612.USD","BK4548","LU0417516902.SGD","LU0307460666.USD","LU0359202008.SGD","HK0000320223.HKD","LU2039709279.SGD","LU0348825331.USD","LU1242518857.USD","LU0051755006.USD","LU0708995583.HKD","LU1720050803.USD","BK1576","BK4531","LU0039217434.USD","09688","LU0823426480.USD","LU0348827113.USD","IE00B5MMRT66.SGD","02269","LU0819121731.USD","01477","LU0140636845.USD","LU0979878070.USD","BK1588","LU2778985437.USD","LU0417516571.SGD","LU0823426308.USD","LU3063872942.SGD","LU0856984785.SGD","LU0043850808.USD","LU0327786744.USD","LU0348784397.USD","LU1961090484.USD","HK0000320264.USD","LU1242518931.SGD","BK1521","BK4526","LU0417516738.SGD","LU0456827905.SGD","BK4588","LU0540923850.HKD","LU2476274308.USD","LU0516423091.SGD","LU0348783233.USD","LU2399975544.HKD"],"gpt_icon":0},{"id":"2590563397","title":"花旗：歌礼制药-BASC30 IIa期数据进一步展现同类最佳潜力 重申“买入/高风险”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2590563397","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590563397?lang=zh_cn&edition=full","pubTime":"2025-12-09 14:17","pubTimestamp":1765261020,"startTime":"0","endTime":"0","summary":"　　花旗发布研报称，预期歌礼制药-B股价将有正面反应； 重申“买入/高风险”评级，目标价32港元。花旗认为歌礼制药公布其口服GLP-1药物ASC30用于治疗肥胖症的美国IIa期研究正向数据进一步展现了ASC30同类最佳的潜力，并增强了未来合作信心。　　ASC30的20毫克、40毫克及60毫克剂量组因不良事件中止治疗的比例仅为7.3%、7.5%及0%，为同类药物中最佳。公司计划于2026年第一季度向美国FDA提交数据并申请II期结束会议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"95d366eecc89ac0bd38c9eeb3f7e1a69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2025-12-09/doc-inhaeqei1565291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01477","01672"],"gpt_icon":0},{"id":"2590395753","title":"港股窄幅震荡，利好刺激 歌礼制药涨超23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590395753","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590395753?lang=zh_cn&edition=full","pubTime":"2025-12-09 10:50","pubTimestamp":1765248600,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　港股速报 | 港股窄幅震荡 利好刺激 歌礼制药涨超23%. 　　12月9日早盘，港股市场小幅高开后窄幅震荡。　　截至发稿，恒生指数报25747.45点，下跌17.31点，跌幅0.07%。　　恒生科技指数报5640.40点，下跌22.15点，跌幅0.39%。　　焦点公司方面，歌礼制药高开高走，截至发稿涨超23%。投资者据此操作，风险自担。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-12-09/doc-inhaeiwp1044224.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-12-09/doc-inhaeiwp1044224.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1191","01672","BK1574","01477","BK1161"],"gpt_icon":0},{"id":"1166068199","title":"港股生物医药股表现活跃！歌礼制药-B涨超20%，圣诺医药-B涨超13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166068199","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166068199?lang=zh_cn&edition=full","pubTime":"2025-12-09 10:02","pubTimestamp":1765245754,"startTime":"0","endTime":"0","summary":"12月9日，港股$生物(000504)$医药股表现活跃，$歌礼制药-B(01672)$涨超20%，$圣诺医药-B(02257)$涨超13%，$昭衍新药(06127)$涨超10%，$药明合联(02268)$涨超4%，$药明生物(02269)$、$药明康德(02359)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"eb673bcce88aebafcbc37fb491eb2df2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1191","01672","BK1574","161726","01477","BK1515","399441","02257"],"gpt_icon":0},{"id":"2590398455","title":"创新药概念股盘初强势 歌礼制药-B(01672)涨20.73% 机构指政策鼓励创新药发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2590398455","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590398455?lang=zh_cn&edition=full","pubTime":"2025-12-09 09:38","pubTimestamp":1765244314,"startTime":"0","endTime":"0","summary":"中信证券表示，2025年12月7日，2025创新药高质量发展大会在广州举行，国家医保局现场发布了2025年《国家基本医疗保险、生育保险和工伤保险药品目录》及《商业健康保险创新药品目录》。该机构认为，国家医保谈判成功率创历史新高，商保目录有望成为重要增量，政策鼓励创新药发展。看好相关创新药及制药企业。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971163","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","SG9999004220.SGD","SG9999014674.SGD","02096","01477","IE00BVYPNP33.GBP","BK1593","IE00BVYPNQ40.USD","BK1191","IE00BYV24P56.USD","BK1141","02157","159992","BK1574","01672","02268","SG9999015952.SGD","IE00BMCWC346.EUR","01952","BK1583","IE00BGHQDM52.EUR","00867","BK1515","SG9999015978.USD","LU2488822045.USD","SG9999015945.SGD","SG9999015986.USD","06978"],"gpt_icon":0},{"id":"1123359126","title":"歌礼制药-B大涨20%！ASC30治疗肥胖症的13周II期研究取得积极的顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1123359126","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123359126?lang=zh_cn&edition=full","pubTime":"2025-12-09 09:31","pubTimestamp":1765243864,"startTime":"0","endTime":"0","summary":"12月9日，歌礼制药-B盘初涨幅扩大至20%！$歌礼制药-B$公布，评估口服小分子GLP-1受体 激动剂ASC30治疗肥胖症的13周II期研究取得积极的顶线结果。在主要终点上，60毫克ASC30的经安慰剂校正后的平均体重下降高达7.7%。在稳态下，ASC30的血药浓度随剂量增加而增加。该ASC30 II期研究因不良事件导致的总体停药率为4.8%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"95d366eecc89ac0bd38c9eeb3f7e1a69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"歌礼制药-B大涨20%！ASC30治疗肥胖症的13周II期研究取得积极的顶线结果","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"gpt_icon":0},{"id":"1150589483","title":"港股开盘 | 恒指高开0.06%，科指低开0.11%！歌礼制药-B飙涨近15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1150589483","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150589483?lang=zh_cn&edition=full","pubTime":"2025-12-09 09:20","pubTimestamp":1765243230,"startTime":"0","endTime":"0","summary":"12月9日，港股开盘，恒指开涨0.06%，科指开跌0.11%。歌礼制药-B涨近15%，ASC30治疗肥胖症的13周II期研究取得积极的顶线结果；万国黄金集团涨超3%，被调入港股通标的证券名单，12月09日起生效。","market":"hk","thumbnail":"https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"95d366eecc89ac0bd38c9eeb3f7e1a69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSI","HSTECH","01672"],"gpt_icon":0},{"id":"1182162311","title":"歌礼制药-B的口服小分子Glp-1药物Asc30在美国的13周二期研究中展示了调整后7.7%的体重减轻且具有更好的胃肠耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1182162311","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182162311?lang=zh_cn&edition=full","pubTime":"2025-12-08 17:43","pubTimestamp":1765186980,"startTime":"0","endTime":"0","summary":"歌礼制药-B的口服小分子Glp-1药物Asc30在参与肥胖或超重的患者中进行的美国13周二期研究中，展现出调整后7.7%的体重减轻，并且具备更好的胃肠耐受性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","01672","BK1161","BK1574"],"gpt_icon":0},{"id":"2589366863","title":"歌礼制药-B：ASC30治疗肥胖症的13周II期研究取得积极的顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2589366863","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589366863?lang=zh_cn&edition=full","pubTime":"2025-12-08 17:33","pubTimestamp":1765186385,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 公布，评估口服小分子GLP-1受体 激动剂ASC30治疗肥胖症的13周II期研究取得积极的顶线结果。在主要终点上，60毫克ASC30的经安慰剂校正后的平均体重下降高达7.7%。在稳态下，ASC30的血药浓度随剂量增加而增加。该ASC30 II期研究因不良事件导致的总体停药率为4.8%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378846.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1191","01672","BK1574","BK1161"],"gpt_icon":0},{"id":"2589381237","title":"歌礼制药-B(01672.HK)涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589381237","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589381237?lang=zh_cn&edition=full","pubTime":"2025-12-08 13:56","pubTimestamp":1765173414,"startTime":"0","endTime":"0","summary":"每经AI快讯，歌礼制药-B(01672.HK)涨超4%，截至发稿涨4.25%，报14.23港元，成交额2682.71万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512083585200140.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512083585200140.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","01477","01672","BK1574","BK1161","BK1515"],"gpt_icon":0},{"id":"2589389033","title":"港股异动 | 歌礼制药-B(01672)涨超4% 1 类新药地尼法司他片上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2589389033","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589389033?lang=zh_cn&edition=full","pubTime":"2025-12-08 13:42","pubTimestamp":1765172527,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B涨超4%，截至发稿，涨4.25%，报14.23港元，成交额2682.71万港元。消息面上，12月4日，CDE 官网显示，歌礼的1类新药地尼法司他片上市申请获得受理。根据该药的临床研究进度，Insight 数据库推测本次申请的适应症为用于治疗中重度寻常性痤疮。兴业证券此前指出，歌礼制药在减重代谢领域持续投入，聚焦减重赛道核心痛点进行深度管线布局。公司引进的痤疮治疗药物ASC40也有望逐渐为公司贡献收入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378689.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1191","01477","BK1515","01672","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascletis.com","stockEarnings":[{"period":"1week","weight":0.0637},{"period":"1month","weight":0.2872},{"period":"3month","weight":0.3034},{"period":"6month","weight":0.5381},{"period":"1year","weight":5.9808},{"period":"ytd","weight":3.8239}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":-0.0351},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0872},{"period":"1year","weight":0.2736},{"period":"ytd","weight":0.295}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"歌礼制药有限公司是一家主要从事医药产品研发、生产和销售的投资控股公司。该公司专注于病毒性疾病、非酒精性脂肪性肝炎（NASH）或原发性胆汁性胆管炎（PBC）及肿瘤领域。该公司的产品管线包括用于慢性乙肝功能性治愈的ASC22、用于呼吸道合胞病毒（RSV）的ASC10、用于人类免疫缺陷病毒（HIV）功能性治愈的ASC22、用於新冠肺炎的ASC10及ASC11、用於NASH的ASC41、用於PBC的ASC42、用于实体瘤的ASC61、用于中、重度痤疮的ASC40等。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.137639},{"month":2,"riseRate":0.714286,"avgChangeRate":0.094063},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.058802},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.059274},{"month":5,"riseRate":0.428571,"avgChangeRate":0.007612},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.024499},{"month":7,"riseRate":0.571429,"avgChangeRate":0.032162},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.037953},{"month":9,"riseRate":0.125,"avgChangeRate":-0.072967},{"month":10,"riseRate":0.5,"avgChangeRate":-0.023171},{"month":11,"riseRate":0.875,"avgChangeRate":0.185422},{"month":12,"riseRate":0.5,"avgChangeRate":0.11407}],"exchange":"SEHK","name":"歌礼制药-B","nameEN":"ASCLETIS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"歌礼制药-B,01672,歌礼制药-B股票,歌礼制药-B股票老虎,歌礼制药-B股票老虎国际,歌礼制药-B行情,歌礼制药-B股票行情,歌礼制药-B股价,歌礼制药-B股市,歌礼制药-B股票价格,歌礼制药-B股票交易,歌礼制药-B股票购买,歌礼制药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}